Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II). The patients had not received prior chemotherapy and were not eligible for radiotherapy and surgery. The overall response rate was 25% (5 of 20 patients). One patient with adenocarcinoma achieved a complete response, four achieved a partial response and three a minor response. In four patients the disease was stable. The response did not vary strictly with initial performance status as patients with a Karnofsky score of less than 70% also showed a median survival of 7.5+ months. The FAM II combination was very well tolerated, particularly regarding nausea and vomiting; the latter occurred in only one patient. No patient required a reduction in the drug dose because of leukopenia or thrombocytopenia.